'Royal Attitudes to the Atlantic Slave Trade and Abolition in the Eighteenth and Early Nineteenth Centuries'.

Recent historiography has placed particular emphasis on the social origins and influence of individuals who took opposing sides in debate on the abolition of the slave trade between 1787 and 1807. There is no doubt that family networks and connections influenced patterns of pro-slavery and abolitionist support. Despite this familial focus, comparatively little attention has been paid to the attitudes and interventions in debate of King George III and his family. As early as 1808, Thomas Clarkson’s History of the Rise, Progress, and Accomplishment of the Abolition of the African Slave-Trade by the British Parliament, recorded how Prince William Henry, duke of Clarence, and his younger cousin, Prince William Frederick, second duke of Gloucester and Edinburgh, held diametrically opposed views on the issue. Evidence that has recently come to light in the Royal Archives makes it possible to assess whether the divide between George III’s son and nephew points to a royal family riven by disagreement on the rights and wrongs of slavery. By broadening the canvas of study to include other royal dukes, this article contributes to a much fuller understanding of the family’s reaction to one of the most pressing moral and economic questions of the day. Their views were not just a matter of their own personal opinions; their interventions in debate affected (and on balance, impeded) the progress of abolition and had direct repercussions on the lives of hundreds of thousands of enslaved Africans

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection.

Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin. In an open-label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in children aged 3 to <12 years chronically infected with genotype 2 or for 24 weeks in patients with genotype 3. Patients aged 3 to <6 years weighing <17 kg received sofosbuvir 150 mg, and patients aged 3 to <6 years weighing ≥17 kg and all patients aged 6 to <12 years received sofosbuvir 200 mg once daily. Intensive pharmacokinetic sampling conducted in each age group confirmed the appropriateness of sofosbuvir doses. For all patients, ribavirin dosing was determined by baseline weight (up to 1,400 mg/day, two divided doses). The primary efficacy endpoint was sustained virologic response 12 weeks after therapy (SVR12). Fifty-four patients were enrolled (41 aged 6 to <12 years and 13 aged 3 to <6 years). Most were treatment naïve (98%) and infected perinatally (94%). All but one patient achieved SVR12 (53/54, 98%; 95% confidence interval, 90%-100%). The patient who did not achieve SVR12 was a 4-year-old who discontinued treatment after 3 days because of "abnormal drug taste." The most commonly reported adverse events in patients aged 6 to <12 years were vomiting (32%) and headache (29%), and those in patients aged 3 to <6 years were vomiting (46%) and diarrhea (39%). One 3-year-old patient had a serious adverse event of accidental ribavirin overdose requiring hospitalization for monitoring; this patient completed treatment and achieved SVR12. Conclusion: Sofosbuvir plus ribavirin was well tolerated and highly effective in children aged 3 to <12 years with chronic HCV genotype 2 or 3 infection

Exploring Graphic Novels for Elementary Science and Mathematics

Abstract Prompted by the recent surge in the popularity and utilization of graphic novels in the elementary classroom as well as trends toward the publication of content-focused graphic novels, the research described in this study was designed to explore educators' perspectives toward the medium as well as the issue of quality in graphic novels with science or math content. Qualitative results recorded through evaluation forms and focus-group sessions revealed the existence of variance in participants' perspectives. However, these results also indicate potential benefits and perceived problems or concerns

The Absolute Risk of Venous Thrombosis after Air Travel: A Cohort Study of 8,755 Employees of International Organisations

In a cohort study of 8,755 employees of large international organizations followed for 38,910 person-years, Suzanne Cannegieter and colleagues find a risk of one thrombosis per 4,656 long-haul flights